<DOC>
	<DOCNO>NCT00263003</DOCNO>
	<brief_summary>Study Objectives : - To demonstrate reduction office Blood Pressure follow 8-week regimen irbesartan / hydrochlorothiazide use irbesartan reference . - To demonstrate reduction office Blood Pressure 4-week regimen irbesartan / hydrochlorothiazide use irbesartan reference . - To compare response rate ( define office Systolic Blood Pressure/Diastolic Blood Pressure reduce 10mmHg Week 0 ) patient 4-week 8-week regimen irbesartan / hydrochlorothiazide versus irbesartan . - To compare proportion patient require titration 4-week regimen irbesartan/hydrochlorothiazide versus irbesartan - To ascertain safety tolerability irbesartan / hydrochlorothiazide versus irbesartan administer daily</brief_summary>
	<brief_title>Irbesartan/Hydrochlorothiazide Irbesartan Treatment Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients mild moderate hypertension office Diastolic Blood Pressure ( DBP ) 90109 mmHg and/or Systolic Blood Pressure ( SBP ) 140179 mmHg All woman childbearing potential must negative urine pregnancy test within week prior initiation therapy female pregnant breast feed office DBP ≥ 110 mmHg office SBP ≥ 180 mmHg history significant cardiovascular disease include : acute myocardial infarction within six month ischemic heart disease require medication . cerebrovascular disease history significant renal disease include : serum creatinine &gt; 3.0 mg/dl . creatinine clearance &lt; 30 ml/min . severe biliary cirrhosis cholestasis refractory hypokalemia , hypercalcemia history autoimmune disease , collagen vascular disease , multiple drug allergy , bronchospastic disease malignancy require current medication hepatic disease indicate follow : SGOT SGPT &gt; 3 x upper limit normal . Serum bilirubin &gt; 2 x upper limit normal . condition therapy , investigator 's opinion , indicated product ( ) label may pose risk patient interfere study objective . investigational drug give within 30 day initiation therapy , participation clinical study enrol protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>